```html

Zidovudine (AZT) Toxicity

What is Zidovudine (AZT) Toxicity?

Zidovudine, also known as AZT or azidothymidine, is a nucleoside reverse‑transcriptase inhibitor (NRTI) that has been used for more than three decades to treat Human Immunodeficiency Virus (HIV) infection. While it is an effective component of antiretroviral therapy (ART), high plasma concentrations or prolonged exposure can lead to toxicity. Zidovudine (AZT) toxicity refers to a collection of adverse effects that occur when the drug’s dose exceeds the body’s ability to metabolize and eliminate it safely. Toxicity can manifest as bone‑marrow suppression, liver injury, neurologic changes, and metabolic disturbances. Recognizing these signs early is crucial because untreated toxicity can progress to life‑threatening complications.

Common Causes

Several factors increase the risk of AZT toxicity. The most common include:

• Overdose or prescribing errors – accidental or intentional ingestion of a dose higher than recommended.
• Impaired renal function – reduced clearance leads to drug accumulation.
• Severe hepatic disease – the liver metabolizes AZT; cirrhosis or hepatitis can raise drug levels.
• Drug‑drug interactions – medications that inhibit glucuronidation (e.g., allopurinol, probenecid) or compete for the same metabolic pathways.
• Advanced age – older adults often have decreased organ reserve.
• Concurrent use of other NRTIs – additive bone‑marrow suppression can potentiate toxicity.
• Genetic polymorphisms affecting the enzyme UDP‑glucuronosyltransferase (UGT2B7), which is responsible for AZT clearance.
• Malnutrition or low body weight – dosages based on standard weight may become excessively high.
• Pregnancy – physiological changes can alter drug pharmacokinetics, sometimes necessitating dose adjustments.
• Non‑adherence to monitoring – missing scheduled lab tests (CBC, liver enzymes) may allow toxicity to develop unnoticed.

Associated Symptoms

The clinical picture of AZT toxicity is often systemic because the drug interferes with DNA synthesis in rapidly dividing cells. Commonly reported symptoms include:

• Bone‑marrow suppression: anemia (fatigue, pallor, shortness of breath), neutropenia (recurrent infections), thrombocytopenia (easy bruising, nosebleeds).
• Liver injury: jaundice, right‑upper‑quadrant discomfort, elevated transaminases.
• Gastrointestinal upset: nausea, vomiting, loss of appetite, abdominal cramps.
• Neurologic effects: headache, dizziness, peripheral neuropathy, rare central nervous system depression.
• Myopathy: muscle weakness, especially proximal muscles.
• Metabolic abnormalities: hyperlactatemia and lactic acidosis, especially when AZT is combined with other NRTIs.
• Dermatologic signs: rash, pruritus, or photosensitivity.
• Fatigue and malaise – often a nonspecific but early clue.

When to See a Doctor

Because many of the early signs of AZT toxicity overlap with common side effects of HIV therapy, patients should maintain a low threshold for seeking medical advice. Contact a healthcare professional promptly if you notice:

• Persistent or worsening fatigue combined with shortness of breath.
• New bruising, petechiae, or unexplained bleeding.
• Fever, chills, or any sign of infection that does not improve within 48 hours.
• Yellowing of the skin or eyes, or dark urine.
• Severe nausea/vomiting that prevents you from staying hydrated.
• Unexplained muscle pain or weakness, especially if you have difficulty climbing stairs.
• Rapid heart rate, severe abdominal pain, or a feeling of “cold sweats,” which may herald lactic acidosis.

Timely evaluation can prevent progression to serious organ damage.

Diagnosis

Diagnosing AZT toxicity involves a combination of clinical assessment, laboratory testing, and sometimes imaging. The typical work‑up includes:

1. Detailed medical history

• Medication list (including over‑the‑counter drugs and supplements).
• Duration and dosage of AZT therapy.
• Renal and hepatic function history.
• Recent changes in diet, weight, or other illnesses.

2. Physical examination

• Signs of anemia (pallor, tachycardia).
• Evidence of infection or bleeding.
• Abdominal exam for hepatomegaly or tenderness.

3. Laboratory studies

• Complete blood count (CBC) with differential: looks for anemia, neutropenia, thrombocytopenia.
• Liver function tests (AST, ALT, ALP, bilirubin): detect hepatocellular injury.
• Renal panel (creatinine, BUN, eGFR): assesses drug clearance capacity.
• Lactate level and arterial blood gas: screen for lactic acidosis.
• Serum AZT concentration (if available): rarely used but helpful in suspected overdose.

4. Additional investigations (as indicated)

• Bone marrow biopsy – when cytopenias are severe and the cause is unclear.
• Abdominal ultrasound or CT – if hepatic or splenic enlargement is suspected.
• Electrocardiogram – to rule out cardiac involvement in severe metabolic acidosis.

Guidelines from the CDC and the Mayo Clinic recommend baseline labs before initiating AZT and repeat testing every 1–3 months for the first year of therapy.

Treatment Options

Management hinges on the severity of toxicity, the underlying cause, and the patient’s overall health. The goals are to stop drug accumulation, restore affected organ function, and prevent complications.

1. Immediate actions

• Discontinue or hold AZT: In most cases, stopping the drug halts progression of toxicity.
• Supportive care: Intravenous fluids for dehydration, anti‑emetics for nausea, and analgesics for pain.
• Correct metabolic abnormalities: Administer bicarbonate for severe acidosis only under close monitoring.

2. Hematologic support

• Red blood cell transfusions for symptomatic anemia (Hb < 8 g/dL or as clinically indicated).
• Granulocyte colony‑stimulating factor (G‑CSF) for profound neutropenia.
• Platelet transfusions if platelet count < 10,000/µL or bleeding occurs.

3. Hepatic management

• Withdrawal of other hepatotoxic medications.
• Consider N‑acetylcysteine (NAC) in cases resembling drug‑induced liver injury, though evidence specific to AZT is limited.

4. Switch to an alternative ART regimen

After stabilization, an HIV specialist will select an alternative backbone—commonly tenofovir alafenamide (TAF) plus emtricitabine (FTC) with a third agent such as an integrase inhibitor (e.g., dolutegravir). The new regimen should avoid agents that also suppress bone marrow.

5. Long‑term monitoring

• Repeat CBC and liver panel 1–2 weeks after drug cessation, then monthly until values normalize.
• Assess viral load to ensure HIV suppression is maintained with the new regimen.

6. Home‑based measures

• Stay well‑hydrated; aim for at least 2 L of water per day unless fluid‑restricted.
• Consume a balanced diet rich in iron, folate, and vitamin B12 to aid hematologic recovery.
• Avoid alcohol and over‑the‑counter NSAIDs that can further irritate the liver or gut.
• Keep a symptom diary to share with your provider.

Prevention Tips

While not every case of AZT toxicity can be avoided, the following strategies markedly reduce risk:

• Adhere to prescribed dosing: Do not adjust the dose without clinician approval.
• Regular laboratory monitoring: CBC, liver enzymes, and renal function as per guidelines.
• Review all medications: Inform your provider about any new drugs, supplements, or herbal products.
• Maintain a healthy weight: Dosage calculations are often weight‑based; significant weight loss may necessitate dose reduction.
• Stay vaccinated: Influenza and pneumococcal vaccines reduce infection risk when neutropenia occurs.
• Report side effects early: Early communication prevents progression to severe toxicity.
• Pregnancy planning: Discuss potential dose adjustments with your obstetrician and HIV specialist.
• Educate yourself: Knowing the signs of bone‑marrow suppression and liver injury empowers you to act quickly.

Emergency Warning Signs

Key Takeaways

Zidovudine (AZT) remains an important drug in the HIV treatment arsenal, but toxicity can be serious. Recognizing risk factors, staying on top of routine labs, and promptly reporting symptoms are the cornerstones of safe therapy. When toxicity is identified, swift discontinuation of AZT, supportive care, and transition to an alternative antiretroviral regimen usually lead to full recovery.

For further reading, see:

• Mayo Clinic. Azidothymidine (AZT) – Side effects and safety.
• CDC. HIV Treatment Guidelines.
• NIH. Guidelines for Antiretroviral Therapy in Adults and Adolescents.
• World Health Organization. WHO Consolidated Guidelines on the Use of Antiretroviral Drugs.
• Cleveland Clinic. Zidovudine (AZT) Overview.

```